At CFO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Baden-Wurttemberg based CFO’ operating in the Biotechnology space. If you think a CFO’ is missing from this list, feel free to contact our editor on [email protected].
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Pierre Kemula
CFO of CureVac
joined CureVac in October 2016. Before joining CureVac, he was Chief Financial Officer of Pixium Vision where he successfully contributed to the listing of the company on Euronext in Paris, and Vice President Corporate Finance, Treasury and Financial Markets at Ipsen. He had earlier worked with major strategy consulting firms (Roland Berger, Bossard Consultants and Gemini Consulting). He holds a Bachelor of Science in Management Sciences from the London School of Economics (LSE) in the United Kingdom.
Follow Pierre Kemula:
About CureVac: CureVac is a clinical-stage biopharmaceutical company that provides prophylactic and therapeutic application of messenger RNA.
Oliver Schlüter
Managing Director and CFO of Novaliq
Oliver Schlüter is managing director, CFO of Novaliq. He has 20+ years of professional experience within the fields of Finance and Life Sciences. Oliver Schlüter was CFO of CureVac GmbH from 2010 to 2015. During his tenure at CureVac, he was instrumental in the transformation of a 70 employee R&D-driven company to a 170-employee customer-centric and value-focused corporation that entered into several strategic partnerships with in-house cGMP-manufacturing. From the time of his appointment in 2010, the company secured more than USD 250 million in funding and increased the company value more than tenfold to more than €1 billion. He holds a PhD in computational finance and also studied business administration.
Follow Oliver Schlüter:
About Novaliq: Novaliq is a pharmaceutical company for the development and commercialization of first- and best-in-class ocular therapeutics.
Reinhard Rubow
Chief Financial Officer of Retina Implant
Reinhard Rubow worked in various leading financial functions at several well-known companies before becoming commercial director of the Institute of Natural Sciences and Medicine (NMI) at the University of Tübingen in Reutlingen. From there, he ventured into the start-up company Retina Implant AG.
Follow Reinhard Rubow:
About Retina Implant: Retina Implant is a biotech company which develops subretinal implants for partially sighted and blind patients.
Benjamin Steimle
CFO & Co-Founder of Cytena
Follow Benjamin Steimle:
About Cytena: Cytena develops single-cell printing technology for cell research and professional diagnostics.
Peter Willinger
CFO of Apogenix
Peter Willinger is Chief Financial Officer of Apogenix. He also directs the human resources, legal/IP, quality assurance, and public relations departments at Apogenix. Before joining Apogenix, he was CFO of LION bioscience AG/SYGNIS Pharma AG in Heidelberg, Germany, where he oversaw the finance, investor relations, and corporate development departments. From 1998 to 2004, he was Director Controlling und Vice President Global Finance & Operations at LION bioscience AG. Following his studies in business administration at the Baden-Wuerttemberg Cooperative State University Mannheim, Willinger worked as a controller with Rudolf Wild GmbH in Heidelberg, Germany, for eight years before joining the finance department of LION bioscience AG.
Follow Peter Willinger:
About Apogenix: Apogenix is a biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases.
Matthias Klaften
COO & CFO of amcure
Matthias Klaften is one of the co-founders of amcure. As Chief Operating Officer and Chief Financial Officer, he is responsible for the operative management of amcure. He has expertise in the development of high-tech projects and has advised many biotech start-up companies as business development manager and consultant for Spin-Off projects at the department of Innovation Management at the Karlsruhe Institute of Technology (KIT). Prior to that, he was a project leader for several medtech projects funded by the Helmholtz Society, the Federal Ministry of Education and Research (BMBF) and the Federal Ministry of Economics and Technology (BMWi). Dr. Klaften received his PhD from the Institute for Experimental Genetics at the Helmholtz Zentrum München.
Follow Matthias Klaften:
About amcure: amcure is a clinical-stage company develops peptide-based compounds for the treatment of highly metastatic forms of squamous cancer.